Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ:BIIB)

193.81 -7.37 (-3.66%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
57 58 Next >
News headline image
3 Millionaire-Maker Biotech Stocks to Buy Before the Window Closes ↗
Here are three millionaire maker drug stocks from companies whose drugs could make truly staggering profits. 
Via InvestorPlace
News headline image
Biotech Battlefields: 3 Stocks to Watch Amid Wall Street Turmoil ↗
There is opportunity in a crisis. Key biotech stocks amid turmoil could be the greatest deals on the market today. 
Via InvestorPlace
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Reata Pharmaceuticals, Inc. (Nasdaq – RETA), Talaris Therapeutics, Inc. (Nasdaq – TALS), Inpixon® (Nasdaq – INPX), Amedisys, Inc. (Nasdaq – AMED)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Biogen (NASDAQ: BIIB) Acquires Reata (NASDAQ: RETA) to Boost its Neurological Therapeutics Portfolio, Including SKYCLARYS®
Reata's Acquisition to Propel Biogen's Growth Strategy Biogen Inc. (NASDAQ: BIIB) and Reata Pharmaceuticals, Inc. (NASDAQ: RETA) have announced a 
Via Spotlight Growth
News headline image
Health Care Company Biogen Announces Acquisition of Reata Pharmaceuticals ↗
 
Via Benzinga
News headline image
I Was Concerned About Biogen Until I Heard These 11 Words From Its CEO ↗
Biogen shares have stagnated in recent years, but the company has a plan to change that. 
Via The Motley Fool
News headline image
Stock Market Rallies Amid Huge Earnings, Fed Rate Hike, Inflation Data: Weekly Review ↗
Despite Thursday's downside reversal, the major indexes had a solid advance. 
Via Investor's Business Daily
News headline image
Reata's Acquisition Fits Biogen's Strategy Despite High Cost: Analyst Says High Level Regulatory Scrutiny Not Anticipated ↗
Earlier today, Biogen Inc (NASDAQ: BIIB) agreed to acquire Reata Pharmaceuticals Inc (NASDAQ: RETA) for $172.50 per share in cash, reflecting an enterprise value of  
Via Benzinga
News headline image
Analyst Ratings for Biogen ↗
 
Via Benzinga
News headline image
Biogen (BIIB) Q2 2023 Earnings Call Transcript ↗
BIIB earnings call for the period ending June 30, 2023. 
Via The Motley Fool
News headline image
Biogen Inc. Tops Q2 Earnings And Revenue Estimates ↗
Biogen Inc. came out with quarterly earnings of $4.02 per share. 
Via Talk Markets
News headline image
Why Is Reata Pharmaceuticals (RETA) Stock Up 53% Today? ↗
Reata Pharmaceuticals (RETA) stock is soaring higher on Friday as investors react to an acquisition deal with Biogen (BIIB). 
Via InvestorPlace
News headline image
Biogen Announces $7.3 Billion Acquisition Of Reata Pharmaceuticals ↗
Reata stock surged more than 50% on the news. 
Via Investor's Business Daily
News headline image
Biogen Bolsters Rare Disease Portfolio, Agrees To Buy Reata Pharmaceuticals With Enterprise Value Of $7.3B ↗
Biogen Inc (NASDAQ: BIIB) has agreed to acquire Reata Pharmaceuticals Inc (NASDAQ: RETA) for $172.50 per share in cash, reflecting an enterprise value of  
Via Benzinga
News headline image
Biogen to Acquire Reata Pharmaceuticals
From Biogen Inc.
Via GlobeNewswire
Neuroinflammation A Key Indicator For Alzheimer’s, But Current Treatments Show Little Success In Reducing Or Even Increase It — Could This Rising Company Have The Answer?
--News Direct-- 
Via News Direct
News headline image
Better Big Biotech Buy: Vertex vs. Biogen ↗
These companies have a track record of billion-dollar earnings. 
Via The Motley Fool
News headline image
Biogen Earnings Preview ↗
 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For July 27, 2023 ↗
 
Via Benzinga
News headline image
Why Sage Therapeutics Stock Is Tumbling Today ↗
A partner's perceived lack of enthusiasm for an upcoming regulatory decision is spooking investors today. 
Via The Motley Fool
News headline image
Why Biogen Stock Got Sick Today ↗
While the company has won approval for a promising drug, it's cutting costs in the wake of that regulatory green light. 
Via The Motley Fool
News headline image
Biogen Unusual Options Activity ↗
 
Via Benzinga
News headline image
Ron DeSantis Escapes Car Accident Unhurt En Route To Campaign Event, TikTok Takes On Twitter, Analysts Expect Nvidia's AI Revenues To Reach $300B In Five Years: Today's Top Stories ↗
The Hill Ron DeSantis Escapes Car Accident Unhurt En Route To Campaign Event 
Via Benzinga
News headline image
WMT Stock Alert: Is Walmart Really Worth $210? ↗
Walmart (WMT) stock is in the news Tuesday as investors react to the latest coverage from Piper Sandler analyst Edward Yruma. 
Via InvestorPlace
News headline image
MBLY Stock Alert: Morgan Stanley Restarts Mobileye Coverage ↗
Mobileye (MBLY) stock is on the move Tuesday after Morgan Stanley analyst Adam Jonas renewed coverage of the company's shares. 
Via InvestorPlace
News headline image
Biogen Layoffs 2023: What to Know About the Latest BIIB Job Cuts ↗
Biogen (BIIB) layoffs are on the way as the company seeks further profits with its upcoming Alzheimer's disease drug launch. 
Via InvestorPlace
News headline image
Biogen Q2 Earnings Tops Expectations, Shift Resources To Higher Value Area(s), Layoff 1K Staff ↗
Biogen Inc (NASDAQ: BIIB) posted Q2 FY23 sales of $2.46 billion, beating the con 
Via Benzinga
News headline image
Nasdaq Futures Rise Ahead Of Microsoft, Alphabet Earnings: Analyst Warns Of Volatility From Fed's Message 'Crafting' ↗
 
Via Benzinga
News headline image
All Eyes On Biogen's Alzheimer's Drug, A Big Potential Payday, Ahead Of Earnings ↗
Analysts expect Biogen to report a a decline in both profits and sales in Q2. 
Via Investor's Business Daily
News headline image
Goldman Sachs, Charles Schwab And This Healthcare Stock On CNBC's 'Final Trades' ↗
On CNBC’s "Halftime Report Final Trades," Joshua Brown of Ritholtz Wealth Management named Biogen Inc. 
Via Benzinga
< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
57 58 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.